William L. Warren

Eversheds Sutherland (Atlanta)
Lawyer (Partner)

Bill Warren advises clients on strategic intellectual property issues primarily in the life sciences sector, but also in a number of other industries. The majority of his practice focuses on patents related to biotechnology, medical device and pharmaceutical inventions. Bill prosecutes patents, counsels clients on patent validity and infringement issues and prepares product clearance opinions and development strategies. He also negotiates technology transfer licensing agreements and conducts intellectual property due diligence. Bill is chair of the firm’s biotechnology and life sciences team, and previously led Eversheds Sutherland (US)’s Intellectual Property Practice Group. He also protects trademarks and copyrights and, when necessary, participates in litigating intellectual property issues. In particular, he counsels various entities on Hatch-Waxman generic pharmaceutical and related biosimilars issues. For more than two decades, Bill has worked with clients ranging from multinational corporations, to early-stage entrepreneurial companies, to nonprofit university and science research centers. He is a frequent speaker and writer on developments in patent law affecting the life sciences industry.

Linked authors

Eversheds Sutherland (Paris)
Eversheds Sutherland (London)
Eversheds Bianchini (Roma)
Freshfields Bruckhaus Deringer (Rome)
Wierzbowski Eversheds (Warsaw)


389 Bulletin

John L. North, William L. Warren The US Court of Appeals holds that if the terms of pay for delay settlements between the brand name and generic pharma companies are within the "scope of the patent" antitrust law is not implicated (Abbott / Geneva / Zenith)


A recent 11th Circuit case, Valley Drug Co. v. Geneva Pharmaceuticals, Inc., sheds light on the complex intersection of patent and antitrust law in the context of a settlement agreement between a name brand pharmaceutical manufacturer and two allegedly infringing generic manufacturers that (...)

Send a message